Biofocus opens Cambridge, U.K., facility; Study shows low 8% PhI oncology dropout rate;

> Galapagos subsidiary Biofocus opened a new 60,000-square-foot facility in Cambridge, U.K., to aid its drug discovery services. Story

> ClinEdge teamed up with ClinicalConnection, a database website for clinical trial searches, notifications and patient referrals. Release

> A study showed that the overall dropout rate for oncology Phase I trials sits at a low 8%, with the average across all therapeutic areas much higher at 47.2%. Release

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.